Skip to Main content Skip to Navigation
Journal articles

Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug‐resistant chronic lymphocytic leukemia

Abstract : The different types of drug resistance encountered in chronic lymphocytic leukemia (CLL) cannot be fully accounted for by the 17p deletion (and/or TP53 mutation), a complex karyotype (CK), immunoglobulin heavy-chain variable region genes (IGHV) status and gene mutations. Hence, we sought to assess the associations between recurrent genomic abnormalities in CLL and the disease's development and outcome. To this end, we analyzed 64 samples from patients with CLL and gain of the short arm of chromosome 2 (2p+), which is frequent in late-stage and relapsed/refractory CLL. We found that fludarabine/cyclophosphamide/rituximab (a common first-line treatment in CLL) is not effective in removing the 2p+ clone - even in samples lacking a CK, the 17p deletion or unmutated IGHV. Our results suggest strongly that patients with CLL should be screened for 2p+ (using karyotyping and fluorescence in situ hybridization) before a treatment option is chosen. Longer follow-up is now required to evaluate bendamustine-rituximab, ibrutinib, and idelalisib-rituximab treatments.
Complete list of metadatas

https://hal.sorbonne-universite.fr/hal-02273234
Contributor : Gestionnaire Hal-Su <>
Submitted on : Wednesday, August 28, 2019 - 4:18:53 PM
Last modification on : Tuesday, February 23, 2021 - 11:10:02 AM

Identifiers

Citation

Fotini Kostopoulou, Clementine Gabillaud, Elise Chapiro, Béatrice Grange, Julie Tran, et al.. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug‐resistant chronic lymphocytic leukemia. Cancer Medicine, Wiley, 2019, 8 (6), pp.3131-3141. ⟨10.1002/cam4.2123⟩. ⟨hal-02273234⟩

Share

Metrics

Record views

477

Files downloads

994